Placeholder

Xyrem: Awakenings

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1937. Categories: , .

Product Description

Cataplexy, a symptom of the chronic sleep disorder narcolepsy, is an alarming condition, resulting in sudden, brief episodes of muscle weakness or paralysis brought on by strong emotions such as laughter, anger, surprise, or anticipation. In severe attacks, the patient may collapse and be unable to move for up to several minutes.
Until recently, there were no approved treatments for people with this condition. That changed July 17, 2002, when the Food and Drug Administration approved Xyrem (sodium oxybate) oral solution for the treatment of cataplexy. Xyrem is the only drug approved for treating cataplexy. Of the estimated 140,000 Americans who suffer from narcolepsy, between 60% and 90% experience cataplexy. Orphan Medical Inc. developed Xyrem under the FDA’s Orphan Drug Act of 1983, which provides market exclusivity to companies that develop products for small…

Sidebar:
Market Facts
Understanding Narcolepsy
Recently Approved Orphan Drugs

Experts on this topic
Jed Black, M.D. Director, Stanford Sleep Disorders Clinic, Stanford University Sleep Research Center, Stanford, Calif.; The ­Stanford Sleep Disorders Clinic was ­founded to diagnose and treat patients who have difficulties falling asleep or ­staying asleep at night, problems with excessive daytime sleepiness, or other ­medical problems that may occur during, or be exacerbated, during sleep
John Bullion. Chairman and CEO, Orphan Medical Inc., Minnetonka, Minn.; Orphan Medical acquires, develops, and markets pharmaceuticals of high medical value for inadequately treated and ­uncommon diseases treated by specialist physicians
Bob Cloud. Executive Director, Narcolepsy Network, Cincinnati; Narcolepsy Network is a national, non-profit, patient-based ­organization whose mission is to educate the public and healthcare professionals about ­narcolepsy
Mali Einen. Clinical research coordinator, Center for Narcolepsy Research in the­ ­Stanford Sleep Disorders Center, Stanford, Calif.; The Stanford Center for Narcolepsy Research, founded in the 1980s, is the world’s leader in narcolepsy research
Donald Ellis, Pharm.D. Partner, Thomas Weisel Partners LLC, San Francisco; Thomas Weisel Partners is a merchant bank providing institutional brokerage, private client services, private equity, and asset management
Andrew Forman. Senior Analyst and Managing Director, Healthcare Research Group, Friedman, Billings, Ramsey & Co., Arlington, Va.; FBR & Co. is a financial ­holding company that focuses capital and financial expertise on six industry sectors: financial services, real estate, technology, energy, healthcare, and diversified ­industries
Bill Houghton, M.D. VP, Chief Medical Officer, Chief Scientific Officer, Orphan ­Medical Inc., Minnetonka, Minn.; Orphan Medical acquires, develops, and markets pharmaceuticals of high medical value for inadequately treated and uncommon ­diseases treated by specialist physicians
Mark Perrin. Executive VP, Chief ­Commercial Officer, Orphan Medical Inc.; Minnetonka, Minn., Orphan Medical acquires, develops, and markets ­pharmaceuticals of high medical value for inadequately treated and uncommon ­diseases treated by specialist physicians

FEEDBACK